Leonie Adam, Katharina Zoldan, Maike Hofmann, Michael Schultheiss, Dominik Bettinger, Christoph Neumann‐Haefelin, Robert Thimme, Tobias Boettler – 7 September 2018 – Primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) are the most common cholestatic liver diseases. While PBC is generally accepted to be an autoimmune disorder characterized by pathognomonic autoantibodies against mitochondrial antigens, the pathogenesis of PSC is less precisely defined; however, some degree of altered immunity toward autoantigens has been suggested.

Carla Colombo, Gianfranco Alicandro – 6 September 2018

Sarah E. Kleinstein, Matthew Rein, Manal F. Abdelmalek, Cynthia D. Guy, David B. Goldstein, Anna Mae Diehl, Cynthia A. Moylan – 5 September 2018 – Nonalcoholic fatty liver disease (NAFLD) is a heterogeneous disease with highly variable outcomes. Patients with simple steatosis typically experience a benign course, whereas those with more advanced liver injury, nonalcoholic steatohepatitis (NASH), and advanced stage fibrosis suffer increased risk for complications such as cirrhosis, hepatic decompensation, and liver cancer.

Carlos J. Pirola, Diego Flichman, Hernán Dopazo, Tomas Fernández Gianotti, Julio San Martino, Cristian Rohr, Martin Garaycoechea, Carla Gazzi, Gustavo O. Castaño, Silvia Sookoian – 5 September 2018 – We report on the presence of a rare nonsense mutation (rs149847328, p.Arg227Ter) in the glucokinase regulator (GCKR) gene in an adult patient with nonalcoholic fatty liver disease (NAFLD), morbid obesity, and type 2 diabetes; this patient developed a progressive histological form of the disease.

The new UNOS organ allocation policy is scheduled to go into effect in December 2018. Work your way through the changes and challenges with the Chair of the AASLD Liver Transplantation SIG and Editor-in-Chief of Liver Transplantation in this first of a series of webinars brought to you by a collaboration of the SIG and journal.Paul Martin (Moderator) Paul Martin MD, FAASLD is Professor of Medicine and Chief of the Divisions of Gastroenterology and Hepatology at the University of Miami, USA.

Binita Kamath, Cara Mack – 4 September 2018

Jingwen Wang, Jianwen Chen, Yang Liu, Xianhuang Zeng, Mingcong Wei, Shaoshuai Wu, Qiushuang Xiong, Feifei Song, Xu Yuan, Yu Xiao, Yun Cao, Changyong Li, Lang Chen, Mingxiong Guo, Yun‐Bo Shi, Guihong Sun, Deyin Guo – 4 September 2018 – Hepatitis B virus (HBV) is a major risk factor for the development and progression of hepatocellular carcinoma. It has been reported that viral infection can interfere with cellular microRNA (miRNA) expression and participate in the pathogenesis of oncogenicity.

Zobair Younossi, Frank Tacke, Marco Arrese, Barjesh Chander Sharma, Ibrahim Mostafa, Elisabetta Bugianesi, Vincent Wai‐Sun Wong, Yusuf Yilmaz, Jacob George, Jiangao Fan, Miriam B. Vos – 4 September 2018 – Over the past 2 decades, nonalcoholic fatty liver disease (NAFLD) has grown from a relatively unknown disease to the most common cause of chronic liver disease in the world. In fact, 25% of the world’s population is currently thought to have NAFLD. Nonalcoholic steatohepatitis (NASH) is the subtype of NAFLD that can progress to cirrhosis, hepatocellular carcinoma (HCC), and death.

Zobair Younossi, Frank Tacke, Marco Arrese, Barjesh Chander Sharma, Ibrahim Mostafa, Elisabetta Bugianesi, Vincent Wai‐Sun Wong, Yusuf Yilmaz, Jacob George, Jiangao Fan, Miriam B. Vos – 4 September 2018 – Over the past 2 decades, nonalcoholic fatty liver disease (NAFLD) has grown from a relatively unknown disease to the most common cause of chronic liver disease in the world. In fact, 25% of the world’s population is currently thought to have NAFLD. Nonalcoholic steatohepatitis (NASH) is the subtype of NAFLD that can progress to cirrhosis, hepatocellular carcinoma (HCC), and death.

Aditya Ambade, Patrick Lowe, Karen Kodys, Donna Catalano, Benedek Gyongyosi, Yeonhee Cho, Arvin Iracheta‐Vellve, Adeyinka Adejumo, Banishree Saha, Charles Calenda, Jeeval Mehta, Eric Lefebvre, Pamela Vig, Gyongyi Szabo – 4 September 2018 – Kupffer cell and macrophage (MØ) activation contributes to steatosis, inflammation, and fibrosis in alcoholic liver disease (ALD).